Ferroptosis biomarkers predict tumor mutation burden's impact on prognosis in HER2-positive breast cancer

Figure 7 The mutation profile of different subgroups in the TCGA cohort. A: Relationship between tumor mutation burden (TMB) and risk scores; B: Relationship between TMB groups and risk groups; C: TMB in low- and high-risk subgroups; D: Kaplan–Meier survival analysis of a new subset in a cohort of HER2+ breast cancer patients combined with the risk group and TMB. TMB: Tumor mutation burden; NS: Not significant; BC: Breast cancer.